Valo Therapeutics Oy Shareholder Update 

On June 7th the German Regulatory Authority (PEI) granted clinical trial approval for our Phase 1 study to be conducted with PetiCRAd-1 at two sites in Germany. All regulatory and ethics related conditions have been met. 

Read the full Shareholder update here